Population screening for PCa using prostate specific antigen (PSA) testing is currently not recommended, due to ongoing controversies regarding the net balance of benefits against harms, including potential harms of prostate biopsy [5-7]. The gene discussed is KLK3; the disease is posterior cortical atrophy.